Blog – Labcoat

Portfolio Company Vedanta Announces Promising Phase 2 Trial Results

By Sal Daher, CFA Vedanta Biosciences announced October 5th, 2021 that its experimental therapy VE303 reduces the likelihood of recurrence of C. diff. by more than 80%. BARDA exercises $23.8 million to fund Phase 3 clinical trials starting in 2022. Heres a link to the press release: https://www.businesswire.com/news/home/20211005005154/en/PureTech-Founded-Entity-Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA

Why I Put My Money on Daphne Zohar

Blog / By Sal Daher, CFA

by Sal Daher, CFA Daphne Zohar is pioneering a distinctive approach to innovation in biotech that does not attract enough attention. It involves unusual openness to new ideas coupled with disciplined vetting of the ideas’ technical and commercial possibilities. She also has keen eye for talent. The results are astonishing. I know this first hand …

Why I Put My Money on Daphne Zohar Read More »

AI + Lasers + Your Cells Is the New Formula for Personalized Medicine

Blog / By Sal Daher, CFA

Cellino Biotech is mixing three disciplines: machine learning, laser physics and cell biology to create affordable treatments from your own cells. Imagine a future where you are diagnosed with a degenerative disease, such as Parksinson’s or Alzheimer’s, and within days an effective treatment, made from your own cells, is ready to be administered. That’s the …

AI + Lasers + Your Cells Is the New Formula for Personalized Medicine Read More »

The Three Ways to Invest in Early-Stage Biotech

Blog / By Sal Daher, CFA

We are entering the Decade of Biotech as powerful technologies begin to bear plentiful fruit. Many of these technologies will be accessible to academic founders working in shared lab spaces and funded by angel investors. Angels can invest in these early-stage biotech companies in three main ways, (1) directly on the capitalization table [the list …

The Three Ways to Invest in Early-Stage Biotech Read More »

Why We Are Focused on Early-Stage Biotech

Blog / By Sal Daher, CFA

By Sal Daher, CFA From the sixty plus angel investments I made since the early 1990s most of the value has been created among the life science companies. That’s why I’m focusing my angel investing exclusively on life science startups. I expect the coming decade to see growing opportunities for angel investors to help academic …

Why We Are Focused on Early-Stage Biotech Read More »

Why Invest in Early-Stage Biotech

Blog / By Matias

By Sal Daher, CFA The miracle of the mRNA COVID vaccines, brought to us by two startups, leaves no doubt as to the promise of biotech. While experts expected the vaccines to take years, these startups designed theirs in days and were saving millions in a matter of months. The icing on the cake is …

Why Invest in Early-Stage Biotech Read More »

How Angel Investing in Biotech Differs from Investing in Software

Blog / By Matias

By Sal Daher, CFA Early-stage biotech investing has been the preserve of deep-pocketed investors where angels have feared to tread. The reasons include that it takes a long time to train life scientists, that biology is hard, that life sciences need specialized laboratories with expensive equipment, and that biotechnologies have long and costly product cycles. …

How Angel Investing in Biotech Differs from Investing in Software Read More »